MX2009005045A - Compuestos antiangiogenos. - Google Patents

Compuestos antiangiogenos.

Info

Publication number
MX2009005045A
MX2009005045A MX2009005045A MX2009005045A MX2009005045A MX 2009005045 A MX2009005045 A MX 2009005045A MX 2009005045 A MX2009005045 A MX 2009005045A MX 2009005045 A MX2009005045 A MX 2009005045A MX 2009005045 A MX2009005045 A MX 2009005045A
Authority
MX
Mexico
Prior art keywords
compounds
angiogenic compounds
targeting
antibody
linked
Prior art date
Application number
MX2009005045A
Other languages
English (en)
Spanish (es)
Inventor
Curt Bradshaw
Jing-Yu Lai
Venkata Doppalapudi
Abhijit Bath
Dingguo Liu
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Publication of MX2009005045A publication Critical patent/MX2009005045A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2009005045A 2006-11-10 2007-11-12 Compuestos antiangiogenos. MX2009005045A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86536006P 2006-11-10 2006-11-10
US93983007P 2007-05-23 2007-05-23
US94532907P 2007-06-20 2007-06-20
PCT/IE2007/000110 WO2008056346A2 (en) 2006-11-10 2007-11-12 Anti-angiogenic compounds

Publications (1)

Publication Number Publication Date
MX2009005045A true MX2009005045A (es) 2009-11-10

Family

ID=39364902

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005045A MX2009005045A (es) 2006-11-10 2007-11-12 Compuestos antiangiogenos.

Country Status (18)

Country Link
US (3) US8288349B2 (https=)
EP (2) EP2368908A3 (https=)
JP (2) JP4897050B2 (https=)
KR (2) KR20120043028A (https=)
CN (1) CN101611053B (https=)
AT (1) ATE520712T1 (https=)
AU (1) AU2007318912B2 (https=)
BR (1) BRPI0718591A2 (https=)
CA (1) CA2669207A1 (https=)
DK (1) DK2089425T3 (https=)
IL (1) IL198581A (https=)
MX (1) MX2009005045A (https=)
MY (1) MY146985A (https=)
NO (1) NO20092203L (https=)
NZ (1) NZ576751A (https=)
PL (1) PL2089425T3 (https=)
PT (1) PT2089425E (https=)
WO (1) WO2008056346A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2368908A3 (en) * 2006-11-10 2011-10-12 CovX Technologies Ireland Limited Anti- angiogenic compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2010036930A1 (en) * 2008-09-26 2010-04-01 Javad Parvizi Methods and kits for detecting joint infection
RU2012157167A (ru) * 2010-07-12 2014-08-20 КовЭкс Текнолоджиз Айэлэнд Лимитед Полифункциональные антительные конъюгаты
JP2014500248A (ja) * 2010-11-05 2014-01-09 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗糖尿病化合物
WO2013003606A1 (en) 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
CN104125838B (zh) 2011-12-20 2016-12-14 辉瑞公司 制备肽缀合物和连接基的改进方法
EP3447071A1 (en) 2012-01-09 2019-02-27 Pfizer Healthcare Ireland Mutant antibodies and conjugation thereof
JP6219923B2 (ja) 2012-03-28 2017-10-25 アムジェン インコーポレイテッド Ｄｒ５受容体アゴニストの組み合わせ
SMT201800589T1 (it) 2013-06-12 2019-01-11 Pharis Biotec Gmbh Peptidi con attivita' antagoniste contro cxcr4 naturale
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
KR20180090290A (ko) 2015-12-04 2018-08-10 시애틀 지네틱스, 인크. 사차화 튜불리신 화합물들의 컨쥬게이트들
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
AU2018259856B2 (en) 2017-04-28 2025-05-01 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
DK0527798T3 (da) 1990-04-06 1997-12-15 Jolla Cancer Res Found Fremgangsmåde og sammensætning til behandling af thrombose
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6326176B1 (en) 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
JP2003516121A (ja) 1999-09-27 2003-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 不可逆的に結合するエンジニアリング抗体
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20030045477A1 (en) 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EP1443963B1 (en) * 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
US6737524B2 (en) * 2002-03-25 2004-05-18 Paul K. Smith Activated polyethylene glycol compounds
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP2368908A3 (en) * 2006-11-10 2011-10-12 CovX Technologies Ireland Limited Anti- angiogenic compounds

Also Published As

Publication number Publication date
MY146985A (en) 2012-10-15
BRPI0718591A2 (pt) 2013-12-03
DK2089425T3 (da) 2011-10-10
WO2008056346B1 (en) 2008-12-04
KR20090090331A (ko) 2009-08-25
EP2089425B1 (en) 2011-08-17
US8912148B2 (en) 2014-12-16
NZ576751A (en) 2011-10-28
CA2669207A1 (en) 2008-05-15
PL2089425T3 (pl) 2012-02-29
ATE520712T1 (de) 2011-09-15
US8288349B2 (en) 2012-10-16
EP2368908A2 (en) 2011-09-28
CN101611053A (zh) 2009-12-23
IL198581A (en) 2015-10-29
US20150057431A1 (en) 2015-02-26
JP2012121886A (ja) 2012-06-28
WO2008056346A3 (en) 2008-10-23
AU2007318912B2 (en) 2011-03-03
US20080166364A1 (en) 2008-07-10
PT2089425E (pt) 2011-10-17
IL198581A0 (en) 2011-08-01
JP2010509315A (ja) 2010-03-25
EP2089425A2 (en) 2009-08-19
US20120301431A1 (en) 2012-11-29
AU2007318912A1 (en) 2008-05-15
NO20092203L (no) 2009-08-10
JP4897050B2 (ja) 2012-03-14
KR20120043028A (ko) 2012-05-03
CN101611053B (zh) 2015-06-03
WO2008056346A2 (en) 2008-05-15
EP2368908A3 (en) 2011-10-12
KR101309948B1 (ko) 2013-09-23

Similar Documents

Publication Publication Date Title
MY146985A (en) Anti-angiogenic compounds
WO2006094269A3 (en) Anti-angiogenic compounds
MX2009007146A (es) Conjugados porcion del factor ix-polimero que tienen ligadura que se puede liberar.
HN2012000437A (es) Nuevos agentes anticancer y la preparacion de dichos agentes
WO2011006143A3 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
MX342709B (es) Tratamiento contra el cancer.
NZ710729A (en) Amatoxin derivatives
GB2466912A (en) Compositions and methods for treating lysosomal disorders
SG195196A1 (en) Dual targeting
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
MY161415A (en) A homeopathic formulation
MX2008016039A (es) Preparacion de glucano.
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
WO2008070268A3 (en) Pharmaceutical compositions
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
WO2010014258A3 (en) Conjugates having a releasable linkage
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
WO2008075205A3 (en) Improved process for the preparation of voriconazole
MA32935B1 (fr) Agent prophylactique/therapeutique pour le cancer
MX2009008249A (es) Composicion farmaceutica que comprende derivado de camptotecina.
WO2010077310A3 (en) Amide derivatives of ethacrynic acid
MX2010008668A (es) Composiciones fungicidas que comprenden 3'-bromo-2,3,4,6'-tetramet oxy-2'-6-dimetilbenzofenona.
MX2010002032A (es) Uso de flibanserina para el tratamiento de sintomas vasomotores.
MX2009005117A (es) Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.

Legal Events

Date Code Title Description
FG Grant or registration